LONDON (Alliance News) - ValiRx PLC Tuesday provided a positive update on the ongoing phase I/II dose escalation clinical trial of its cancer drug VAL201.
The company said that over the last month the trial has continued to demonstrate safety and tolerability and no significant adverse effects have been recorded. The next dose escalation has been approved as a result of safety and tolerability data, which ValiRx said "may prove sufficient to show anti-tumour activity."
"Again it is good to be reporting that the VAL201 trial continues to proceed well and as planned. I am pleased to say that, at this stage, a good safety profile has been seen and potential efficacy continues to be noticed," said Chief Executive Officer Satu Vainikka in a statement.
"We are now nearing dose levels that we originally projected would be therapeutically significant and as such, I enthusiastically look forward to VAL201's continued clinical trial progress and to updating investors accordingly," Vainikka added.
Shares in ValiRx are trading up 3.3% at 34.10 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)